Related Experiment Videos
Silent myocardial ischemia. Rationale for management
C J Pepine1, K Coy, C R Lambert
1University of Florida, Gainesville.
Postgraduate Medicine
|February 29, 1988
Summary
Most coronary artery disease patients experience silent ischemic episodes, which impact prognosis. Therapies like beta-blockers and calcium antagonists can modify these silent events, improving patient outcomes.
Area of Science:
- Cardiology
- Ischemic Heart Disease
Background:
- Silent myocardial ischemia is prevalent in coronary artery disease patients, even those without symptoms.
- Silent ischemia is increasingly recognized as a significant prognostic factor in various patient groups.
Purpose of the Study:
- To review the role of silent ischemia in coronary artery disease prognosis.
- To discuss therapeutic strategies for managing silent ischemia and its associated risks.
Main Methods:
- Review of recent studies on silent ischemia in coronary artery disease.
- Analysis of evidence regarding the impact of various therapies on silent ischemic episodes.
Main Results:
- The majority of ischemic episodes in coronary artery disease patients are silent and correlate with prognosis.
- Nitroglycerin, isosorbide dinitrate, beta-adrenergic blockers, and calcium antagonists can modify silent ischemia.
- Combination therapy with beta-blockers and calcium antagonists appears most effective.
- Angina characteristics do not predict prognosis, unlike certain features of silent ischemia.
Conclusions:
- Silent ischemia significantly influences prognosis in coronary artery disease patients.
- Therapeutic interventions targeting silent ischemia, particularly combination therapy, can modify its frequency and duration.
- Focus should be on improving outcomes in high-risk patients, considering silent ischemia characteristics over angina alone.